6-K - Zentek Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Zentek Ltd. announced that its wholly-owned subsidiary Triera Biosciences plans to offer contract research organization services for custom aptamer discovery, biosensor enablement, and machine-learning classification, backed by an exclusive 20-year worldwide royalty-bearing license from McMaster University. This targets high-priority infectious disease and oncology detection markets to generate client-funded revenue while retaining IP ownership.

Key Takeaways

1Triera Biosciences plans to begin CRO services for custom aptamer discovery via SELEX, biosensor engineering, and ML classification.

2Exclusive worldwide royalty-bearing license from McMaster University for 20 years on aptamer applications developed with Dr. Yingfu Li's team.

3Services targeted at pharmaceutical, biotechnology, and diagnostics organizations in Canada, United States, and Europe.

4Aptamer catalogue includes influenza A, SARS-CoV-2, VEGF, syphilis, norovirus, and Clostridioides difficile with sub-nanomolar binding affinities (Kd).

5Asset-light model with client-funded engagements and Triera retaining all IP ownership.

6CEO Mohammed Jiwan stated services align with urgent diagnostic gaps in infectious disease and oncology.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (2)

6-K

FORM 6-K

99.1

EXHIBIT 99.1